Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
Immatics Biomarker Screening
Sponsor: Immatics US, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS6510
U.S. Govt. ID: NCT03760952
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to find out if you can take part in one or more of the treatment studies sponsored by Immatics. The "treatment studies" involve adoptive cellular therapy (ACT), a type of therapy in which T cells (a type of immune cell) are given to a participant to help the body fight diseases, such as cancer. If your tumor has one or more of the required biomarkers, you will be asked if you want to consider participating in one of the treatment studies. If you do, you will be asked to consent to the treatment study that corresponds to the biomarker(s) that are present in your tumor.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a confirmed diagnosis of advanced and/or metastatic solid tumors? Yes No
Do you have a life expectancy of greater than 6 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162